Drug pricing challenges diabetes king Novo Nordisk

By Ben Hirschler and Mette Fraende COPENHAGEN (Reuters) - Drug pricing is emerging as a key challenge for Novo Nordisk, the world's biggest insulin producer, whose previously unstoppable growth has started to flag, according to the Danish firm's chief executive. Lars Sorensen is certain of one thing: the number of potential customers for his products is going to keep on rising as a global obesity epidemic tips more people into type 2 diabetes in the West and many developing nations. But he has a mounting fight on his hands when it comes to securing a good price for insulin and other diabetes treatments from cost-conscious reimbursement authorities around the world. "Pricing is going to be challenging," Sorensen said in an interview at the drugmaker's headquarters in Bagsvaerd on the outskirts of Copenhagen, where a new spiral office complex inspired by the insulin molecule is under construction.



via Health News Headlines - Yahoo! News http://news.yahoo.com/drug-pricing-challenges-diabetes-king-novo-nordisk-122453157--finance.html